

**Amendments to the Claims:**

This listing of claims will replace all previous versions and listings of claims in the application:

1. (currently amended) A method for the therapeutic treatment of psoriasis in a human, comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2, and blocks ErbB2 signaling through the MAP kinase pathway.
2. (currently amended) The method of claim 1 wherein the antibody blocks ligand activation of an ~~ErbB~~ErbB2 receptor.
3. (previously presented) The method of claim 2 wherein the antibody blocks binding of monoclonal antibody 2C4 to ErbB2.
- 4.-7. (canceled)
8. (previously presented) The method of claim 1 wherein the antibody binds the same epitope in the extracellular domain of ErbB2 as that bound by monoclonal antibody 2C4.
9. (previously presented) The method of claim 8 wherein the antibody comprises monoclonal antibody 2C4 or humanized 2C4.
10. (previously presented) The method of claim 1 wherein the antibody is an antibody fragment.
11. (previously presented) The method of claim 11 wherein the antibody fragment is a Fab fragment.
12. (previously presented) The method of claim 1 wherein the antibody is not conjugated with a cytotoxic agent.
13. (previously presented) The method of claim 10 wherein the antibody fragment is not conjugated with a cytotoxic agent.
14. (previously presented) The method of claim 1 wherein the antibody is conjugated with a cytotoxic agent.

15. (canceled)

16. (previously presented) The method of claim 1 comprising administering at least one dose of the antibody to the human in an amount from about 0.5mg/kg to about 30mg/kg.

17.- 46. (canceled)